Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
BEVERLY, Mass. and TORONTO, May 01, 2018 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that David Wolf, President and CEO of Hamilton Thorne Ltd., will present at the 2018 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Hotel Toronto on Thursday May 3, 2018 at 11:00 a.m. Eastern Time.
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly
traded and private companies through presentations and private meetings.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
David Wolf, President & CEO
Hamilton Thorne Ltd.
978-921-2050
[email protected]
Michael Bruns, CFO
Hamilton Thorne Ltd.
978-921-2050
[email protected]
Glen Akselrod
Bristol Investor Relations
905-326-1888
[email protected]
